1985

Employees 90

Official distributors 85

International sales 85%

Annual R&D+i budget 40%

Countries 90

m2 of facilities in Barcelona 8500

The company has been committed to the development and marketing of top-quality products right from the start, with scientifically proven results.

Our progress is linked to ongoing research and collaboration with hospitals, universities and experienced specialists from the sector as the company works closely with these to research and develop new treatments.

Story

1990 - 1999
Development of a wider portfolio and expansion to international trade

Ongoing collaboration with the medical sector has enabled mesoestetic to develop numerous innovative products to treat other aesthetic problems associated with signs and symptoms of aging and figure concerns.

The results and effectiveness of these products are known worldwide as the company now markets its products in more than 50 countries through distributors and renowned aesthetics professionals.

Cosmelan

2002
World-leading treatment for pigmented blemishes: cosmelan®

mesoestetic® is the world leader in the treatment of hyperpigmentation after reformulating one of our most successful products with the launch of cosmelan®.

2010
mesohyal®: customizable anti-aging solutions

Global innovation with the widest range of injectable medical devices with CE marking for intradermal aesthetic injections.

The company is at the forefront of aesthetic medicine, offering a range of products to treat a variety of aging-related problems in a customized, targeted manner.

2011 - 2014
New Headquarters with Biotechnology Unit and Medical Unit

Our current facilities, covering over 8,500 m2, which were opened in 2011, are proof of our commitment to growth and excellence.

Our new headquarters are home to our production lines (cosmeceuticals, nutraceuticals, medications and injectable medical devices) and our Biotechnology Unit and Medical Unit for Observational Control and Surveillance, which give us the ability to research even more effective active ingredients and conduct in vitro and in vivo testing on the state-of-the-art products we manufacture.

The company exports more than 85% of sales, and our products and treatments are available in more than 80 countries across all continents.

2015
First topical medication: anestopic®

In 2015, the company obtained authorization from the Spanish Agency of Medicines and Medical Devices (Agencia Española del Medicamento y Producto Sanitario) to manufacture and market its first-ever medication. 

Anestopic® is a local anesthetic cream for topical application designed to temporarily numb areas of the body prior to certain dermatological and aesthetic procedures.

Leave the professional area Leave the exclusive area of professionals and access the web for consumers